Business
Board Changes
Physiomics plc announced that Executive Director and CEO Peter Sargent will step down on May 29, 2026, with Non-Executive Chairman Dr. Jim Millen prepared to resume the Executive Chairman role to ensure business continuity. The company expects total revenues to be in line with market expectations and will release its interim results for the half-year ending December 31, 2025, in early March 2026. Dr. Sargent's departure follows a period of significant progress, including notable revenue increases, record contract wins, and the launch of a new biometrics service line and personalised medicine initiative. Disclaimer*
About this update from Physiomics Plc
3 December 2025 Physiomics plc ("Physiomics" or the "Company") Board Changes Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biometrics company supporting the development of new therapeutics and personalised medicine solutions, announces that Peter Sargent will be stepping down from his role as Executive Director and CEO of the Company to pursue other opportunities, with effect from 29 May 2026. The Company has commenced its search to appoint a new CEO and further announcements will be made in due course. Dr Jim Millen, currently Non-Executive Chairman, has confirmed that he will be available to resume the position of Executive Chairman from the date of Dr Sargent's departure, for as long as required to ensure business continuity in the event a suitable replacement has not been found by that date. Dr Millen was formerly the CEO of the Company from 2016 to 2024, during which time he grew the business from total income of under £300k to a peak of over £900k, as well as securing a major contract with long term client Merck KGaA and kicking off the Company's personalised medicine initiative. The Company expects to deliver total revenues in line with market expectations and will be posting its interim results for the half-year ending 31 December 2025 during the first week of March 2026, in line with its usual reporting timetable. Dr Jim Millen, Non-executive Chairman of Physiomics, commented: " Following our strategic review in early 2024, the Company has made considerable progress on its principal growth initiatives. Pete has played an instrumental role in achieving these objectives, contributing to notable revenue increases and record levels of contract wins over the past two years. We are excited for the next stage in Physiomics' growth and at the same time wish Pete all the very best and thank him for enabling us to start the current financial year ending 30 June 2026 with a record level of contracted projects, a new biometrics service-line already generating revenue, and significant progress across our personalised medicine dosing software initiative." For more information about Physiomics and its services, please visit www.physiomics.co.uk . Enquiries: Physiomics plc Dr Peter Sargent, CEO +44 (0)1235 841575 Hybridan LLP (Broker) Claire Louise Noyce +44 (0) 203 764 2341 Strand Hanson Ltd (NOMAD) James Dance & James Bellman +44 (0)20 7409 3494 Notes to Editor About Physiomics Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 140 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.